CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 3, May/June 2011
152
AFRICA
2001;
50
: 2199–2202.
30. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S,
et al
. Resistin is not associated with insulin sensitivity or the metabolic
syndrome in humans.
Diabetologia
2005;
48
: 2330–2333.
31. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM.
Positional cloning of the mouse obese gene and its human homologue.
Nature
1994;
372
: 425–432.
32. Ahima RS. Revisiting leptin’s role in obesity and weight loss.
J Clin
Invest
2008;
118
: 2380–2383.
33. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D,
et
al
. Leptin stimulates fatty-acid oxidation by activating AMP-activated
protein kinase.
Nature
2002;
415
: 339–343.
34. Muoio DM, Dohm GL, Fiedorek FT, Jr, Tapscott EB, Coleman RA.
Leptin directly alters lipid partitioning in skeletal muscle.
Diabetes
1997;
46
: 1360–1363.
35. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action
and leptin resistance.
A Rev Physiol
2008;
70
: 537–556.
36. Badman MK, Flier JS. The adipocyte as an active participant in energy
balance and metabolism.
Gastroenterology
2007;
132
: 2103–2115.
37. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ.
J Clin
Endocrinol Metab
2004;
89
: 2548–2556.
38. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y,
Matsubara K. cDNA cloning and expression of a novel adipose specific
collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).
Biochem Biophys Res Commun
1996;
221
: 286–289.
39. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel
serum protein similar to C1q, produced exclusively in adipocytes.
J Biol
Chem
1995;
270
: 26746–26749.
40. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T,
Matsuzawa Y,
et al
. Secretion of adiponectin and regulation of apM1
gene expression in human visceral adipose tissue.
Biochem Biophys Res
Commun
2001;
288
: 1102–1107.
41. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J,
et
al
. Paradoxical decrease of an adipose-specific protein, adiponectin, in
obesity.
Biochem Biophys Res Commun
1999;
257
: 79–83.
42. Brichard SM, Delporte ML, Lambert M. Adipocytokines in anorexia
nervosa: a review focusing on leptin and adiponectin.
Horm Metab Res
2003;
35
: 337–342.
43. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE,
et
al
. Hypoadiponectinemia in obesity and type 2 diabetes: close associa-
tion with insulin resistance and hyperinsulinemia.
J Clin Endocrinol
Metab
2001;
86
: 1930–1935.
44. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC,
et al
. Circulating concentrations of the adipocyte protein adiponectin
are decreased in parallel with reduced insulin sensitivity during the
progression to type 2 diabetes in rhesus monkeys.
Diabetes
2001;
50
:
1126–1133.
45. Gilardini L, McTernan PG, Girola A, da Silva NF, Alberti L, Kumar
S,
et al
. Adiponectin is a candidate marker of metabolic syndrome in
obese children and adolescents.
Atherosclerosis
2006;
189
: 401–407.
46. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A,
Velmurugan K,
et al
. Association of low adiponectin levels with the
metabolic syndrome – the Chennai Urban Rural Epidemiology Study
(CURES-4).
Metabolism
2005;
54
: 476–481.
47. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y,
et al
.
Novel modulator for endothelial adhesion molecules: adipocyte-derived
plasma protein adiponectin.
Circulation
1999;
100
: 2473–2476.
48. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hyper-
tension.
Hypertension
2008;
51
: 8–14.
49. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT,
et al
. Proteolytic cleavage product of 30-kDa adipocyte complement-
related protein increases fatty acid oxidation in muscle and causes
weight loss in mice.
Proc Natl Acad Sci USA
2001;
98
: 2005–2010.
50. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-
secreted protein Acrp30 enhances hepatic insulin action.
Nat Med
2001;
7
: 947–953.
51. Yamauchi T, Kamon J, Waki H, TerauchiY, Kubota N, Hara K,
et al
. The
fat-derived hormone adiponectin reverses insulin resistance associated
with both lipoatrophy and obesity.
Nat Med
2001;
7
: 941–946.
52. Okamoto M, Ohara-Imaizumi M, Kubota N, Hashimoto S, Eto K,
Kanno T,
et al
. Adiponectin induces insulin secretion in vitro and in
vivo at a low glucose concentration.
Diabetologia
2008;
51
: 827–835.
53. Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H,
et al
.
Adiponectin stimulates AMP-activated protein kinase in the hypothala-
mus and increases food intake.
Cell Metab
2007;
6
: 55–68.
54. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM.
Determinants of early atherosclerosis in obese children and adolescents.
J Clin Endocrinol Metab
2007;
92
: 3025–3032.
55. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H,
et al
.
Adiponectin acts as an endogenous antithrombotic factor.
Arterioscler
Thromb Vasc Biol
2006;
26
: 224–230.
56. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E,
Alhava E,
et al
. Apelin, orexin-A and leptin plasma levels in morbid
obesity and effect of gastric banding.
Regul Pept
2005;
130
: 7–13.
57. Dray C, Knauf C, Daviaud D, Waget A, Boucher J, Buleon M,
et al
.
Apelin stimulates glucose utilization in normal and obese insulin-
resistant mice.
Cell Metab
2008;
8
: 437–445.
58. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y,
et al
. Impaired
heart contractility in Apelin gene-deficient mice associated with aging
and pressure overload.
Circ Res
2007;
101
: e32–e42.
59. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M,
Kishimoto K,
et al
. Visfatin: a protein secreted by visceral fat that
mimics the effects of insulin.
Science
2005;
307
: 426–430.
60. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR,
et
al
. Plasma visfatin concentrations and fat depot-specific mRNA expres-
sion in humans.
Diabetes
2005;
54
: 2911–2916.
61. Varma V,Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee
MJ,
et al
. Human visfatin expression: relationship to insulin sensitivity,
intramyocellular lipids, and inflammation.
J Clin Endocrinol Metab
2007;
92
: 666–672.
62. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD
biology, metabolism and cancer.
Trends Endocrinol Metab
2009;
20
:
130–138.
63. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A,
et al.
Visceral
adipose tissue-derived serine protease inhibitor: a unique insulin-
sensitizing adipocytokine in obesity.
Proc Natl Acad Sci USA
2005;
102
: 10610–10615.
64. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES,
et al
. Serum
vaspin concentrations in human obesity and type 2 diabetes.
Diabetes
2008;
57
: 372–377.
65. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G,
et al
.
Chemerin is a novel adipokine associated with obesity and metabolic
syndrome.
Endocrinology
2007;
148
: 4687–4694.
66. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC,
Parlee SD,
et al
. Chemerin, a novel adipokine that regulates adipogen-
esis and adipocyte metabolism.
J Biol Chem
2007;
282
: 28175–28188.
67. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS,
Kitazawa R,
et al
. Chemerin enhances insulin signaling and potentiates
insulin-stimulated glucose uptake in 3T3-L1 adipocytes.
FEBS Lett
2008;
582
: 573–578.
68. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M,
et
al
. Chemerin – a new adipokine that modulates adipogenesis via its
own receptor.
Biochem Biophys Res Commun
2007;
362
: 1013–1018.
69. Ernst MC, Issa M, Goralski KB, Sinal CJ. Chemerin exacerbates glucose
intolerance in mouse models of obesity and diabetes.
Endocrinology
2010;
151
: 1998–2007.
70. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A,
et al
. Chemerin is a novel adipocyte-derived factor inducing insulin
resistance in primary human skeletal muscle cells.
Diabetes
2009;
58
:
2731–2740.
71. Akinboboye O, Idris O, Akinboboye O, Akinkugbe O. Trends in coro-
nary artery disease and associated risk factors in sub-Saharan Africans
.
J Hum Hypertens
2003;
17
: 381–387.
72. Tibazarwa K, Ntyintyane L, Sliwa K, Gerntholtz T, Carrington M,
Wilkinson D,
et al
. A time bomb of cardiovascular risk factors in South
Africa: results from the Heart of Soweto Study ‘Heart Awareness Days’.
Int J Cardiol
2009;
132
: 233–239.
73. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovas-
